Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) EBITDA (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of EBITDA data on record, last reported at -$51.5 million in Q3 2025.

  • For Q3 2025, EBITDA fell 33.16% year-over-year to -$51.5 million; the TTM value through Sep 2025 reached -$190.0 million, down 47.26%, while the annual FY2024 figure was -$156.8 million, 323.34% down from the prior year.
  • EBITDA reached -$51.5 million in Q3 2025 per ZBIO's latest filing, up from -$52.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $35.6 million in Q3 2023 and bottomed at -$52.5 million in Q4 2024.
  • Average EBITDA over 3 years is -$31.5 million, with a median of -$37.9 million recorded in 2024.
  • Peak YoY movement for EBITDA: tumbled 208.51% in 2024, then decreased 21.12% in 2025.
  • A 3-year view of EBITDA shows it stood at -$24.7 million in 2023, then plummeted by 112.63% to -$52.5 million in 2024, then grew by 1.89% to -$51.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$51.5 million in Q3 2025, -$52.5 million in Q2 2025, and -$33.6 million in Q1 2025.